Hepatocellular carcinoma targeting agents: Conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid

Ming-Hua Hsu, Szu Chun Wu, Kuan Chuan Pao, Irem Unlu, John N. Gnabre, David E. Mold, Ru Chih C. Huang, Jih Ru Hwu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Cancer has been a primary global health issue for decades, with hepatocellular carcinoma (HCC) resulting in more than half a million new cases annually. With survival rates as low as <5 % after five years, it remains a poorly treated cancer. Nordihydroguaiaretic acid (NDGA), an antioxidant, was previously proven effective against cancer cells. Nitroimidazole derivatives convert into reactive compounds under hypoxic conditions. In this study, eight methylated NDGAs containing a 2- or 4-nitroimidazole moiety were synthesized as leads against HCC. Four of these conjugates, possessing a poly(ethylene glycol) tether, had superior aqueous solubility. These four NDGA-nitroimidazole conjugates were found to inhibit the proliferation HCC Hep3B cells with IC 50 values between 10 and 15 μM. Furthermore, nitroimidazole- conjugated NDGA derivatives exhibit better antiproliferative activity under hypoxic conditions. High performance at low O 2 : Nordihydroguaiaretic acid (NDGA) is a natural product that has been used in many medical research fields. A series of novel nitroimidazole-conjugated NDGA compounds were synthesized and shown to possess good activity against hepatocellular carcinoma (HCC) Hep3B cells. The 4′-trimethyl NDGA derivatives are more potent than their unconjugated counterparts in hypoxic cells. These compounds can therefore be regarded as good HCC-targeting agents.

Original languageEnglish
Pages (from-to)1030-1037
Number of pages8
JournalChemMedChem
Volume9
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Masoprocol
Nitroimidazoles
Hepatocellular Carcinoma
Derivatives
Cells
Neoplasms
Ethylene Glycol
Biological Products
Solubility
Polyethylene glycols
Biomedical Research
Antioxidants
Health

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Hsu, Ming-Hua ; Wu, Szu Chun ; Pao, Kuan Chuan ; Unlu, Irem ; Gnabre, John N. ; Mold, David E. ; Huang, Ru Chih C. ; Hwu, Jih Ru. / Hepatocellular carcinoma targeting agents : Conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid. In: ChemMedChem. 2014 ; Vol. 9, No. 5. pp. 1030-1037.
@article{b58882f7026445a195be043f914b1e8d,
title = "Hepatocellular carcinoma targeting agents: Conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid",
abstract = "Cancer has been a primary global health issue for decades, with hepatocellular carcinoma (HCC) resulting in more than half a million new cases annually. With survival rates as low as <5 {\%} after five years, it remains a poorly treated cancer. Nordihydroguaiaretic acid (NDGA), an antioxidant, was previously proven effective against cancer cells. Nitroimidazole derivatives convert into reactive compounds under hypoxic conditions. In this study, eight methylated NDGAs containing a 2- or 4-nitroimidazole moiety were synthesized as leads against HCC. Four of these conjugates, possessing a poly(ethylene glycol) tether, had superior aqueous solubility. These four NDGA-nitroimidazole conjugates were found to inhibit the proliferation HCC Hep3B cells with IC 50 values between 10 and 15 μM. Furthermore, nitroimidazole- conjugated NDGA derivatives exhibit better antiproliferative activity under hypoxic conditions. High performance at low O 2 : Nordihydroguaiaretic acid (NDGA) is a natural product that has been used in many medical research fields. A series of novel nitroimidazole-conjugated NDGA compounds were synthesized and shown to possess good activity against hepatocellular carcinoma (HCC) Hep3B cells. The 4′-trimethyl NDGA derivatives are more potent than their unconjugated counterparts in hypoxic cells. These compounds can therefore be regarded as good HCC-targeting agents.",
author = "Ming-Hua Hsu and Wu, {Szu Chun} and Pao, {Kuan Chuan} and Irem Unlu and Gnabre, {John N.} and Mold, {David E.} and Huang, {Ru Chih C.} and Hwu, {Jih Ru}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/cmdc.201300521",
language = "English",
volume = "9",
pages = "1030--1037",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

Hepatocellular carcinoma targeting agents : Conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid. / Hsu, Ming-Hua; Wu, Szu Chun; Pao, Kuan Chuan; Unlu, Irem; Gnabre, John N.; Mold, David E.; Huang, Ru Chih C.; Hwu, Jih Ru.

In: ChemMedChem, Vol. 9, No. 5, 01.01.2014, p. 1030-1037.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hepatocellular carcinoma targeting agents

T2 - Conjugates of nitroimidazoles with trimethyl nordihydroguaiaretic acid

AU - Hsu, Ming-Hua

AU - Wu, Szu Chun

AU - Pao, Kuan Chuan

AU - Unlu, Irem

AU - Gnabre, John N.

AU - Mold, David E.

AU - Huang, Ru Chih C.

AU - Hwu, Jih Ru

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Cancer has been a primary global health issue for decades, with hepatocellular carcinoma (HCC) resulting in more than half a million new cases annually. With survival rates as low as <5 % after five years, it remains a poorly treated cancer. Nordihydroguaiaretic acid (NDGA), an antioxidant, was previously proven effective against cancer cells. Nitroimidazole derivatives convert into reactive compounds under hypoxic conditions. In this study, eight methylated NDGAs containing a 2- or 4-nitroimidazole moiety were synthesized as leads against HCC. Four of these conjugates, possessing a poly(ethylene glycol) tether, had superior aqueous solubility. These four NDGA-nitroimidazole conjugates were found to inhibit the proliferation HCC Hep3B cells with IC 50 values between 10 and 15 μM. Furthermore, nitroimidazole- conjugated NDGA derivatives exhibit better antiproliferative activity under hypoxic conditions. High performance at low O 2 : Nordihydroguaiaretic acid (NDGA) is a natural product that has been used in many medical research fields. A series of novel nitroimidazole-conjugated NDGA compounds were synthesized and shown to possess good activity against hepatocellular carcinoma (HCC) Hep3B cells. The 4′-trimethyl NDGA derivatives are more potent than their unconjugated counterparts in hypoxic cells. These compounds can therefore be regarded as good HCC-targeting agents.

AB - Cancer has been a primary global health issue for decades, with hepatocellular carcinoma (HCC) resulting in more than half a million new cases annually. With survival rates as low as <5 % after five years, it remains a poorly treated cancer. Nordihydroguaiaretic acid (NDGA), an antioxidant, was previously proven effective against cancer cells. Nitroimidazole derivatives convert into reactive compounds under hypoxic conditions. In this study, eight methylated NDGAs containing a 2- or 4-nitroimidazole moiety were synthesized as leads against HCC. Four of these conjugates, possessing a poly(ethylene glycol) tether, had superior aqueous solubility. These four NDGA-nitroimidazole conjugates were found to inhibit the proliferation HCC Hep3B cells with IC 50 values between 10 and 15 μM. Furthermore, nitroimidazole- conjugated NDGA derivatives exhibit better antiproliferative activity under hypoxic conditions. High performance at low O 2 : Nordihydroguaiaretic acid (NDGA) is a natural product that has been used in many medical research fields. A series of novel nitroimidazole-conjugated NDGA compounds were synthesized and shown to possess good activity against hepatocellular carcinoma (HCC) Hep3B cells. The 4′-trimethyl NDGA derivatives are more potent than their unconjugated counterparts in hypoxic cells. These compounds can therefore be regarded as good HCC-targeting agents.

UR - http://www.scopus.com/inward/record.url?scp=84899647241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899647241&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201300521

DO - 10.1002/cmdc.201300521

M3 - Article

C2 - 24648164

AN - SCOPUS:84899647241

VL - 9

SP - 1030

EP - 1037

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 5

ER -